|
| Trial | Strategy | Results |
|
| NCT01502774 (CIRCUS trial) | A bolus injection of CsA administered at the onset of myocardial reperfusion in patients with anterior ST-segment-elevation MI (STEMI) | Worsened heart failure during the initial hospitalization, rehospitalization for heart failure, and adverse left ventricular remodeling at 1 year in 59.0% of the 395 patients randomized to cyclosporine and 58.1% of the 396 individuals randomized to placebo [148] |
|
| NCT01374321
(MITOCARE trial) | I.v. bolus administration of TRO40303 (an inhibitor of mPTP opening) in STEMI patients undergoing primary PCI (percutaneous coronary intervention) | TRO40303 did not show any protective effects as compared to placebo in preventing reperfusion injury in STEMI patients treated with primary PCI [149] |
|
| NCT01572909 (EMBRACE STEMI trial) | MTP-131 (a cell-permeable peptide that preserves the integrity of cardiolipin, enhances mitochondrial energetics, and improves myocyte survival during reperfusion in animal models) administration for 1 h among first-time anterior STEMI subjects undergoing primary PCI for a proximal or mid left anterior descending (LAD) artery occlusion | Administration of MTP-131 was not associated with a significant reduction in infarct size or clinical outcomes [150] |
|
| NCT01584453 (NITRITE-AMI trial) | Intracoronary injection of nitrite during primary PCI in STEI patients | The phase II showed that intracoronary nitrite infusion did not change the infarct size. Yet, in a subgroup of patients with TIMI flow ≤1, nitrite reduced infarct size and MACE and improved myocardial salvage index indicating a follow-up with the phase III of the clinical trial [151] |
|
| NCT01388504 (NIAMI trial) | Intravenous sodium nitrite administration immediately prior to PCI in patients with acute STEMI | Myocardial infarct size did not differ between nitrite and placebo groups. There were no significant differences in plasma troponin I and CK area under the curve, left ventricular volumes, and ejection fraction measured at 6–8 days and at 6 months and final infarct size measured at 6 months [152] |
|
